← NewsEarnings

Why Is Innventure (INV) Stock Down? A $100M Run Rate, Withdrawn

Innventure fell about 46% after hours on August 13 after suspending Accelsius' 2026 targets, including a $100M run-rate goal it was chasing with $953,000 of quarterly revenue.

By Atul Ghandhi$INV

TL;DR

  • Innventure (Nasdaq: INV) closed Thursday at $3.60, up 2.27%, then traded near $1.94 after the bell, down about 46%. That is an extended-hours quote around 6:30pm ET on August 13 rather than a settled close, and it sits under the stock's $2.36 52-week low. Friday's regular session decides the headline number.
  • The company suspended Accelsius' 2026 revenue and cash flow targets. What got withdrawn was a roughly $100 million annualized revenue run rate exiting 2026, plus positive operating cash flow by year end.
  • Consolidated Q2 revenue was $953,000, against $476,000 a year earlier. It also fell sequentially, from $1.4 million in Q1.
  • Cash was $41.5 million at June 30 against $59.5 million of operating cash used in the first half. The Q2 10-Q carries substantial doubt about the ability to continue as a going concern.
  • Adjusted EBITDA loss widened to $(22.6) million from $(16.2) million, even as the operating loss narrowed sharply on non-cash comparisons.

More on Earnings: Options Scorecard: The Week of August 3, Graded (37 Calls, 59% Right)

Why Is Innventure (INV) Stock Down?

Innventure pulled the 2026 revenue and cash flow targets for Accelsius, its two-phase liquid cooling business, and reported $953,000 of quarterly revenue against a target that implied roughly $25 million a quarter by December. Management attributed the suspension to "evolving dynamics in the AI infrastructure market, including constraints facing smaller early adopters around power availability, GPU access, and deployment timing."

The Q2 10-Q filed alongside it carries going-concern language. A 46% move looks large against a company this small until you read both disclosures together.

The Board

Board showing Innventure Q2 2026 figures: a suspended $100 million Accelsius run-rate target against $953,000 of consolidated quarterly revenue, $41.5 million of cash against $59.5 million of first-half operating burn, a $22.6 million adjusted EBITDA loss, 84.6 million shares outstanding and a $1.94 after-hours quote on August 13 2026

The target and the revenue base it was measured from.

26x, in Two Quarters

The withdrawn number was an annualized run rate, so measure it against the December quarter. A $100 million annualized run rate exiting 2026 needs roughly $25 million of revenue in Q4.

Innventure's entire company, both operating businesses together, booked $953,000 in the June quarter. Call it a factor of 26, to be delivered in two quarters, by a business whose revenue went $1.4 million in Q1 and $953,000 in Q2. Six-month revenue is $2.4 million.

Management had pointed at roughly $50 million of Accelsius bookings in Q1 as the bridge to that run rate. Bookings and recognised revenue are different things, and the gap between them is where the deployment timing problem shows up: an order that cannot be installed because the customer has no power allocation stays a booking. I read the suspension as an admission that the conversion timeline was never in the company's hands.

The Cash Clock Is the Harder Number

Accelsius' revenue can slip a year without killing anything. The balance sheet is on a shorter timer.

Cash and equivalents were $41.5 million at June 30, plus $5.0 million restricted. Operating activities used $59.5 million in the first half, so the average quarterly burn is close to $29.7 million. Working capital was $11.7 million, notes payable $29.0 million including $16.5 million at a 13.5% rate, and the accumulated deficit is $418.9 million.

Divide the cash by the burn and the runway from June 30 is roughly a quarter and a half at the first-half pace. That is the arithmetic the going-concern paragraph is describing.

Innventure has been funding this with equity. Share count went from 67.7 million at the end of 2025 to 84.6 million at June 30, a quarter more shares in six months, including $50.2 million raised in Q2. That was dilution at prices above $3. The next raise, if it comes at Thursday's after-hours level, costs roughly twice as many shares per dollar.

What the Suspension Says About AI Cooling, and What It Does Not

The reason given is worth reading precisely, because it is narrower than the tape treated it. Management described constraints on smaller early adopters: power availability, GPU access, deployment timing. That is a statement about which customers can install equipment this year, not a statement that direct-to-chip cooling stopped being necessary.

The rest of Thursday agreed with the second half of that. The S&P 500 closed at a record 7,799.73, up 51.23 points or 0.66%, after touching 7,816.70 intraday, and the Nasdaq Composite rose 0.81% to 26,803.51. AI infrastructure spending is not contracting. The money is going to operators who already hold substations and grid allocation, and those are not the customers a pre-revenue cooling vendor gets to sell to yet.

So the split I wrote about on Wednesday, when the Mag 7 slid while memory names ripped, has a third layer under it. Suppliers with shipped product and signed hyperscaler contracts are being paid now. Suppliers whose thesis lands in 2028 have to finance their way there, and the financing window is set by their own cash line rather than by whether the technology works. The sector heatmap shows the first group; it does not show the second, because the second is too small to appear.

Johnson Controls put $25 million into Accelsius, and Accelsius has real engineering behind it. Neither fact pays a $29.7 million quarterly burn.

What Would Change My Mind

A named hyperscaler or OEM design win carrying a dollar value and a delivery date, rather than a relationship. Financing that is not common equity struck near $2. And a Q3 that reverses the sequential revenue decline, because Q1 to Q2 going backwards is the part of this release I find hardest to argue with.

For contrast on the same tape: Leslie's paired a $5.01 EPS with its own going-concern warning on Wednesday, and Eton Pharmaceuticals raised full-year guidance by $25 million on Thursday while generating cash.

The One-Line Read

A $100 million run-rate target withdrawn against $953,000 of quarterly revenue, with going-concern language in the same filing. The cooling technology may well matter in 2028. The equity has to reach November first.

Share

More on Earnings

Updated Every Saturday

The Week Ahead

Every earnings date, Fed event and setup for the current trading week, on one page.

Refreshed Weekly

Earnings Calendar

Who reports next, when, and what consensus and the whisper expect.

The Week-Ahead Brief

Don’t miss next week’s setups. Get the Saturday brief.

Every Saturday: next week’s earnings dates, Fed days and the trades worth watching, from the same desk that writes the week-ahead hub. Free, built for retail investors.

Subscribing means we email you the newsletter and nothing else. No spam, no sharing your address, unsubscribe in one click. See the privacy policy.

Comments

0 total
0/1000
Sign up or sign in to comment

No comments yet. Be the first to drop a take.